The study is designed to determine whether patients who receive sugammadex immediately after tracheal extubation will exhibit a decrease in the incidence of postoperative residual paralysis and an associated decrease in the incidence of postoperative respiratory depression.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
260
Sugammadex will be administered intravenously at 2 mg/kg after routine reversal of anesthesia is performed and subject is extubated.
Placebo will be administered intravenously at 2 mg/kg after routine reversal of anesthesia is performed and subject is extubated.
Mayo Clinic Florida
Jacksonville, Florida, United States
The University of Texas, UTHealth
Houston, Texas, United States
Decreased Minute Ventilation (MV)
The number of subjects who have a MV as defined as \[MV \<80% MV predicted (MVPRED) based on Body Surface Area\]. MV (or respiratory minute volume or minute volume) is the volume of gas inhaled (inhaled minute volume) or exhaled (exhaled minute volume) from a person's lungs per minute.
Time frame: 15---30 minutes after Post-anesthesia care unit (PACU) arrival
Decreased Average Minute Ventilation (MV)
The number of subjects who have an average MV \<80% MV predicted (MVPRED) based on Body Surface Area. MV (or respiratory minute volume or minute volume) is the volume of gas inhaled (inhaled minute volume) or exhaled (exhaled minute volume) from a person's lungs per minute.
Time frame: 15---30 minutes after Post-anesthesia care unit (PACU) arrival
Train of Four (TOF) Ratio
The number of subjects to have a normal TOF ratio (\>0.90) indicative of full neuromuscular recovery in the Post-anesthesia care unit (PACU)
Time frame: upon PACU discharge, approximately 8 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.